Managing pharmaceutical regulation in Germany: Overview and economic assessment
Rising costs in pharmaceutical expenditure have become a major concern for policy makers in Germany over the last years. Therefore the pharmaceutical market in Germany has been increasingly targeted by different kinds of regulations, focussing both on the supply and the demand side, using price, volume and spending controls. Specific regulations include price reductions, reference pricing, pharmacy rebate for sickness funds, increasing co-payments, an aut-idem substitution, parallel imports, negative list, guidelines, and finally spending caps for pharmaceutical expenditure per physicians association. Although it is difficult to attribute certain effects to single measures, some measures like reference pricing and physician spending caps are more effective and long-lasting than others. Although highly disputed among physicians, the spending caps applied between 1993 and 2001 have limited pharmaceutical expenditure for an entire decade. However, while some measures do effectively control expenditures, their effect on allocative efficiency may be negative.
Year of publication: |
2004
|
---|---|
Authors: | Schreyögg, Jonas ; Henke, Klaus-Dirk ; Busse, Reinhard |
Institutions: | Fakultät Wirtschaft und Management, Technische Universität Berlin |
Saved in:
freely available
Saved in favorites
Similar items by person
-
Busse, Reinhard, (2005)
-
The use of cost accounting methodologies to determine prices in German health care
Schreyögg, Jonas, (2005)
-
Eine ökonomische Analyse unterschiedlicher Finanzierungsmodelle der Krankenversorgung in Deutschland
Henke, Klaus-Dirk, (2003)
- More ...